Last 12 months
Inside the activity.
4 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 2 | 0 |
| Jul 2026 | 2 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 30, 2018 Filed Feb 1, 2018 16:30 UTC |
Erlander MarkChief Scientific Officer
|
Tax withholdingCommon Stock | 42,930 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-002487 · doc4.xml · nonDerivative · entry 2 Erlander Mark · CIK 0001651537 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,367 F2 · shares: The reporting person is reporting the withholding by Trovagene, Inc. of 42,930 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the delivery of the Converted Common Stock to the reporting person on January 30, 2018. Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 16:30 UTC |
Erlander MarkChief Scientific Officer
|
Exercise / conversionCommon Stock | 90,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-002487 · doc4.xml · nonDerivative · entry 1 Erlander Mark · CIK 0001651537 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,297 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion upon vesting of restricted stock units into common stock (the "Converted Common Stock"). On April 7, 2017, the reporting person was granted 90,000 restricted stock units, all of which vested on January 30, 2018. Such restricted stock units were previously reported in Table II on a Form 4 filed with the Securities and Exchange Commission on April 10, 2017. Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 16:30 UTC |
WELCH WILLIAM JDirector · Chief Executive Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 130,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-002485 · doc4.xml · derivative · entry 3 WELCH WILLIAM J · CIK 0001237522 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 130,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock. F4 · derivative.exercise_date: On April 7, 2017, the reporting person was granted 130,000 restricted stock units, all of which vested on January 30, 2018. The common stock into which such vested restricted stock units converted on January 30, 2018 is reported in Table I on this Form 4. F4 · derivative.expiration_date: On April 7, 2017, the reporting person was granted 130,000 restricted stock units, all of which vested on January 30, 2018. The common stock into which such vested restricted stock units converted on January 30, 2018 is reported in Table I on this Form 4. Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 16:30 UTC |
WELCH WILLIAM JDirector · Chief Executive Officer
|
Tax withholdingCommon Stock | 62,010 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-002485 · doc4.xml · nonDerivative · entry 2 WELCH WILLIAM J · CIK 0001237522 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 842,645 F2 · shares: The reporting person is reporting the withholding by Trovagene, Inc. of 62,010 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the delivery of the Converted Common Stock to the reporting person on January 30, 2018. Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 16:30 UTC |
WELCH WILLIAM JDirector · Chief Executive Officer
|
Exercise / conversionCommon Stock | 130,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-002485 · doc4.xml · nonDerivative · entry 1 WELCH WILLIAM J · CIK 0001237522 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 904,655 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion upon vesting of restricted stock units into common stock (the "Converted Common Stock"). On April 7, 2017, the reporting person was granted 130,000 restricted stock units, all of which vested on January 30, 2018. Such restricted stock units were previously reported in Table II on a Form 4 filed with the Securities and Exchange Commission on April 10, 2017. Read SEC document |
| January 23, 2018 Filed Jan 25, 2018 17:01 UTC |
Erlander MarkChief Scientific Officer
|
GrantStock Options · Derivative | 672,189 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0000899243-18-001904 · doc4.xml · derivative · entry 1 Erlander Mark · CIK 0001651537 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,782,189 Underlying: Common Stock · 672,189 shares Expires 2028-01-23 F1 · derivative.exercise_date: 522,189 vest immediately upon grant and 50,000 vest on each of 1/23/2019, 2020 and 2021. Read SEC document |
| January 23, 2018 Filed Jan 25, 2018 22:00 UTC |
JACOB GARY SDirector
|
GrantStock Options · Derivative | 54,322 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0000899243-18-001899 · doc4.xml · derivative · entry 1 JACOB GARY S · CIK 0001266802 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 248,101 Underlying: Common Stock · 54,322 shares Expires 2028-01-23 Read SEC document |
| January 23, 2018 Filed Jan 25, 2018 17:00 UTC |
ADAMS THOMAS PHDDirector
|
GrantStock Options · Derivative | 54,322 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0000899243-18-001900 · doc4.xml · derivative · entry 1 ADAMS THOMAS PHD · CIK 0001234366 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 467,277 Underlying: Common Stock · 54,322 shares Expires 2028-01-23 Read SEC document |
| January 23, 2018 Filed Jan 25, 2018 17:01 UTC |
WELCH WILLIAM JDirector · Chief Executive Officer
|
GrantStock Options · Derivative | 662,500 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0000899243-18-001902 · doc4.xml · derivative · entry 1 WELCH WILLIAM J · CIK 0001237522 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,412,500 Underlying: Common Stock · 662,500 shares Expires 2028-01-23 Read SEC document |
| January 23, 2018 Filed Jan 25, 2018 22:05 UTC |
BRANCACCIO JOHN PDirector
|
GrantStock Options · Derivative | 54,322 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0000899243-18-001907 · doc4.xml · derivative · entry 1 BRANCACCIO JOHN P · CIK 0001276551 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,130 Underlying: Common Stock · 54,322 shares Expires 2028-01-23 Read SEC document |
| January 23, 2018 Filed Jan 25, 2018 22:02 UTC |
Billings PaulDirector
|
GrantStock Options · Derivative | 54,322 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0000899243-18-001906 · doc4.xml · derivative · entry 1 Billings Paul · CIK 0001591558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,658 Underlying: Common Stock · 54,322 shares Expires 2028-01-23 Read SEC document |
| January 23, 2018 Filed Jan 25, 2018 22:02 UTC |
Markin Rodney SDirector
|
GrantStock Options · Derivative | 54,322 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0000899243-18-001905 · doc4.xml · derivative · entry 1 Markin Rodney S · CIK 0001393415 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,658 Underlying: Common Stock · 54,322 shares Expires 2028-01-23 Read SEC document |
| January 23, 2018 Filed Jan 25, 2018 22:00 UTC |
Countouriotis AthenaDirector
|
GrantStock Options · Derivative | 54,322 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0000899243-18-001901 · doc4.xml · derivative · entry 1 Countouriotis Athena · CIK 0001571469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,428 Underlying: Common Stock · 54,322 shares Expires 2028-01-23 Read SEC document |
| January 23, 2018 Filed Jan 25, 2018 22:00 UTC |
Tennant StanleyDirector
|
GrantStock Options · Derivative | 54,322 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0000899243-18-001898 · doc4.xml · derivative · entry 1 Tennant Stanley · CIK 0001526214 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,586 Underlying: Common Stock · 54,322 shares Expires 2028-01-23 Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 20:11 UTC Amendment |
Erlander MarkChief Scientific Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 18,750 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-000527 · doc4a.xml · derivative · entry 3 Erlander Mark · CIK 0001651537 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,250 Underlying: Common Stock · 18,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock. F4 · derivative.exercise_date: On January 2, 2017, the reporting person was granted 75,000 restricted stock units, 18,750 of which vested on January 2, 2018. The common stock into which such vested restricted stock units converted on January 2, 2018 is reported in Table I on this Form 4. F4 · derivative.expiration_date: On January 2, 2017, the reporting person was granted 75,000 restricted stock units, 18,750 of which vested on January 2, 2018. The common stock into which such vested restricted stock units converted on January 2, 2018 is reported in Table I on this Form 4. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 20:11 UTC Amendment |
Erlander MarkChief Scientific Officer
|
Tax withholdingCommon Stock | 9,558 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-000527 · doc4a.xml · nonDerivative · entry 2 Erlander Mark · CIK 0001651537 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,297 F2 · shares: The reporting person is reporting the withholding by Trovagene, Inc. of 9,558 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the delivery of the Converted Common Stock to the reporting person on January 2, 2018. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 20:11 UTC Amendment |
Erlander MarkChief Scientific Officer
|
Exercise / conversionCommon Stock | 18,750 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-000527 · doc4a.xml · nonDerivative · entry 1 Erlander Mark · CIK 0001651537 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,855 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion upon vesting of restricted stock units into common stock (the "Converted Common Stock"). On January 2, 2017, the reporting person was granted 75,000 restricted stock units, 18,750 of which vested on January 2, 2018. Such restricted stock units were previously reported in Table II on a Form 4 filed with the Securities and Exchange Commission on January 4, 2017. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 17:15 UTC |
Erlander MarkChief Scientific Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 18,750 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-000481 · doc4.xml · derivative · entry 3 Erlander Mark · CIK 0001651537 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,250 Underlying: Common Stock · 18,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock. F4 · derivative.exercise_date: On January 2, 2017, the reporting person was granted 75,000 restricted stock units, 18,750 of which vested on January 2, 2018. The common stock into which such vested restricted stock units converted on January 2, 2018 is reported in Table I on this Form 4. F4 · derivative.expiration_date: On January 2, 2017, the reporting person was granted 75,000 restricted stock units, 18,750 of which vested on January 2, 2018. The common stock into which such vested restricted stock units converted on January 2, 2018 is reported in Table I on this Form 4. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 17:15 UTC |
Erlander MarkChief Scientific Officer
|
Tax withholdingCommon Stock | 9,558 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-000481 · doc4.xml · nonDerivative · entry 2 Erlander Mark · CIK 0001651537 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,243 F2 · shares: The reporting person is reporting the withholding by Trovagene, Inc. of 9,558 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the delivery of the Converted Common Stock to the reporting person on January 2, 2018. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 17:15 UTC |
Erlander MarkChief Scientific Officer
|
Exercise / conversionCommon Stock | 18,750 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-000481 · doc4.xml · nonDerivative · entry 1 Erlander Mark · CIK 0001651537 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,801 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion upon vesting of restricted stock units into common stock (the "Converted Common Stock"). On January 2, 2017, the reporting person was granted 75,000 restricted stock units, 18,750 of which vested on January 2, 2018. Such restricted stock units were previously reported in Table II on a Form 4 filed with the Securities and Exchange Commission on January 4, 2017. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 22:15 UTC |
JACOB GARY SDirector
|
Exercise / conversionRestricted Stock Units · Derivative | 16,667 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-000482 · doc4.xml · derivative · entry 2 JACOB GARY S · CIK 0001266802 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock. F3 · derivative.exercise_date: On January 2, 2017, the reporting person was granted 16,667 restricted stock units, all of which vested on January 2, 2018. The common stock into which such vested restricted stock units converted on January 2, 2018 is reported in Table I on this Form 4. F3 · derivative.expiration_date: On January 2, 2017, the reporting person was granted 16,667 restricted stock units, all of which vested on January 2, 2018. The common stock into which such vested restricted stock units converted on January 2, 2018 is reported in Table I on this Form 4. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 22:15 UTC |
JACOB GARY SDirector
|
Exercise / conversionCommon Stock | 16,667 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-000482 · doc4.xml · nonDerivative · entry 1 JACOB GARY S · CIK 0001266802 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,954 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion upon vesting of restricted stock units into common stock (the "Converted Common Stock"). On January 2, 2017, the reporting person was granted 16,667 restricted stock units, all of which vested on January 2, 2018. Such restricted stock units were previously reported in Table II on a Form 4 filed with the Securities and Exchange Commission on January 5, 2017. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 21:03 UTC Amendment |
WELCH WILLIAM JDirector · Chief Executive Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-000546 · doc4a.xml · derivative · entry 3 WELCH WILLIAM J · CIK 0001237522 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,000 Underlying: Common Stock · 50,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock. F4 · derivative.exercise_date: On January 2, 2017, the reporting person was granted 200,000 restricted stock units, 50,000 of which vested on January 2, 2018. The common stock into which such vested restricted stock units converted on January 2, 2018 is reported in Table I on this Form 4. F4 · derivative.expiration_date: On January 2, 2017, the reporting person was granted 200,000 restricted stock units, 50,000 of which vested on January 2, 2018. The common stock into which such vested restricted stock units converted on January 2, 2018 is reported in Table I on this Form 4. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 21:03 UTC Amendment |
WELCH WILLIAM JDirector · Chief Executive Officer
|
Tax withholdingCommon Stock | 25,487 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-000546 · doc4a.xml · nonDerivative · entry 2 WELCH WILLIAM J · CIK 0001237522 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 774,655 F2 · shares: The reporting person is reporting the withholding by Trovagene, Inc. of 25,487 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the delivery of the Converted Common Stock to the reporting person on January 2, 2018. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 21:03 UTC Amendment |
WELCH WILLIAM JDirector · Chief Executive Officer
|
Exercise / conversionCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-000546 · doc4a.xml · nonDerivative · entry 1 WELCH WILLIAM J · CIK 0001237522 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 800,142 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion upon vesting of restricted stock units into common stock (the "Converted Common Stock"). On January 2, 2017, the reporting person was granted 200,000 restricted stock units, 50,000 of which vested on January 2, 2018. Such restricted stock units were previously reported in Table II on a Form 4 filed with the Securities and Exchange Commission on January 4, 2017. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 17:16 UTC |
WELCH WILLIAM JDirector · Chief Executive Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-000486 · doc4.xml · derivative · entry 3 WELCH WILLIAM J · CIK 0001237522 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,000 Underlying: Common Stock · 50,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock. F4 · derivative.exercise_date: On January 2, 2017, the reporting person was granted 200,000 restricted stock units, 50,000 of which vested on January 2, 2018. The common stock into which such vested restricted stock units converted on January 2, 2018 is reported in Table I on this Form 4. F4 · derivative.expiration_date: On January 2, 2017, the reporting person was granted 200,000 restricted stock units, 50,000 of which vested on January 2, 2018. The common stock into which such vested restricted stock units converted on January 2, 2018 is reported in Table I on this Form 4. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 17:16 UTC |
WELCH WILLIAM JDirector · Chief Executive Officer
|
Tax withholdingCommon Stock | 25,487 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-000486 · doc4.xml · nonDerivative · entry 2 WELCH WILLIAM J · CIK 0001237522 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 769,905 F2 · shares: The reporting person is reporting the withholding by Trovagene, Inc. of 25,487 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the delivery of the Converted Common Stock to the reporting person on January 2, 2018. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 17:16 UTC |
WELCH WILLIAM JDirector · Chief Executive Officer
|
Exercise / conversionCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-000486 · doc4.xml · nonDerivative · entry 1 WELCH WILLIAM J · CIK 0001237522 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 795,392 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion upon vesting of restricted stock units into common stock (the "Converted Common Stock"). On January 2, 2017, the reporting person was granted 200,000 restricted stock units, 50,000 of which vested on January 2, 2018. Such restricted stock units were previously reported in Table II on a Form 4 filed with the Securities and Exchange Commission on January 4, 2017. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 17:15 UTC |
ADAMS THOMAS PHDDirector
|
Exercise / conversionRestricted Stock Units · Derivative | 16,667 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-000483 · doc4.xml · derivative · entry 2 ADAMS THOMAS PHD · CIK 0001234366 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock. F3 · derivative.exercise_date: On January 2, 2017, the reporting person was granted 16,667 restricted stock units, all of which vested on January 2, 2018. The common stock into which such vested restricted stock units converted on January 2, 2018 is reported in Table I on this Form 4. F3 · derivative.expiration_date: On January 2, 2017, the reporting person was granted 16,667 restricted stock units, all of which vested on January 2, 2018. The common stock into which such vested restricted stock units converted on January 2, 2018 is reported in Table I on this Form 4. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 17:15 UTC |
ADAMS THOMAS PHDDirector
|
Exercise / conversionCommon Stock | 16,667 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-000483 · doc4.xml · nonDerivative · entry 1 ADAMS THOMAS PHD · CIK 0001234366 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 351,959 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion upon vesting of restricted stock units into common stock (the "Converted Common Stock"). On January 2, 2017, the reporting person was granted 16,667 restricted stock units, all of which vested on January 2, 2018. Such restricted stock units were previously reported in Table II on a Form 4 filed with the Securities and Exchange Commission on January 5, 2017. Read SEC document |
| January 02, 2018 Filed Jan 5, 2018 01:16 UTC Amendment |
Tennant StanleyDirector
|
Exercise / conversionRestricted Stock Units · Derivative | 16,667 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-000532 · doc4a.xml · derivative · entry 2 Tennant Stanley · CIK 0001526214 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock. F3 · derivative.exercise_date: On January 2, 2017, the reporting person was granted 16,667 restricted stock units, all of which vested on January 2, 2018. The common stock into which such vested restricted stock units converted on January 2, 2018 is reported in Table I on this Form 4. F3 · derivative.expiration_date: On January 2, 2017, the reporting person was granted 16,667 restricted stock units, all of which vested on January 2, 2018. The common stock into which such vested restricted stock units converted on January 2, 2018 is reported in Table I on this Form 4. Read SEC document |
| January 02, 2018 Filed Jan 5, 2018 01:16 UTC Amendment |
Tennant StanleyDirector
|
Exercise / conversionCommon Stock | 16,667 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-000532 · doc4a.xml · nonDerivative · entry 1 Tennant Stanley · CIK 0001526214 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,061 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion upon vesting of restricted stock units into common stock (the "Converted Common Stock"). On January 2, 2017, the reporting person was granted 16,667 restricted stock units, all of which vested on January 2, 2018. Such restricted stock units were previously reported in Table II on a Form 4 filed with the Securities and Exchange Commission on January 5, 2017. Read SEC document |
| January 02, 2018 Filed Jan 5, 2018 01:16 UTC Amendment |
Billings PaulDirector
|
Exercise / conversionRestricted Stock Units · Derivative | 16,667 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-000531 · doc4a.xml · derivative · entry 2 Billings Paul · CIK 0001591558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock. F3 · derivative.exercise_date: On January 2, 2017, the reporting person was granted 16,667 restricted stock units, all of which vested on January 2, 2018. The common stock into which such vested restricted stock units converted on January 2, 2018 is reported in Table I on this Form 4. F3 · derivative.expiration_date: On January 2, 2017, the reporting person was granted 16,667 restricted stock units, all of which vested on January 2, 2018. The common stock into which such vested restricted stock units converted on January 2, 2018 is reported in Table I on this Form 4. Read SEC document |
| January 02, 2018 Filed Jan 5, 2018 01:16 UTC Amendment |
Billings PaulDirector
|
Exercise / conversionCommon Stock | 16,667 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-000531 · doc4a.xml · nonDerivative · entry 1 Billings Paul · CIK 0001591558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,165 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion upon vesting of restricted stock units into common stock (the "Converted Common Stock"). On January 2, 2017, the reporting person was granted 16,667 restricted stock units, all of which vested on January 2, 2018. Such restricted stock units were previously reported in Table II on a Form 4 filed with the Securities and Exchange Commission on January 5, 2017. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 22:16 UTC |
Tennant StanleyDirector
|
Exercise / conversionRestricted Stock Units · Derivative | 16,667 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-000487 · doc4.xml · derivative · entry 2 Tennant Stanley · CIK 0001526214 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock. F3 · derivative.exercise_date: On January 2, 2017, the reporting person was granted 16,667 restricted stock units, all of which vested on January 2, 2018. The common stock into which such vested restricted stock units converted on January 2, 2018 is reported in Table I on this Form 4. F3 · derivative.expiration_date: On January 2, 2017, the reporting person was granted 16,667 restricted stock units, all of which vested on January 2, 2018. The common stock into which such vested restricted stock units converted on January 2, 2018 is reported in Table I on this Form 4. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 22:16 UTC |
Tennant StanleyDirector
|
Exercise / conversionCommon Stock | 16,667 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-000487 · doc4.xml · nonDerivative · entry 1 Tennant Stanley · CIK 0001526214 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,545 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion upon vesting of restricted stock units into common stock (the "Converted Common Stock"). On January 2, 2017, the reporting person was granted 16,667 restricted stock units, all of which vested on January 2, 2018. Such restricted stock units were previously reported in Table II on a Form 4 filed with the Securities and Exchange Commission on January 5, 2017. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 22:18 UTC |
BRANCACCIO JOHN PDirector
|
Exercise / conversionRestricted Stock Units · Derivative | 16,667 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-000491 · doc4.xml · derivative · entry 2 BRANCACCIO JOHN P · CIK 0001276551 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock. F3 · derivative.exercise_date: On January 2, 2017, the reporting person was granted 16,667 restricted stock units, all of which vested on January 2, 2018. The common stock into which such vested restricted stock units converted on January 2, 2018 is reported in Table I on this Form 4. F3 · derivative.expiration_date: On January 2, 2017, the reporting person was granted 16,667 restricted stock units, all of which vested on January 2, 2018. The common stock into which such vested restricted stock units converted on January 2, 2018 is reported in Table I on this Form 4. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 22:18 UTC |
BRANCACCIO JOHN PDirector
|
Exercise / conversionCommon Stock | 16,667 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-000491 · doc4.xml · nonDerivative · entry 1 BRANCACCIO JOHN P · CIK 0001276551 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,167 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion upon vesting of restricted stock units into common stock (the "Converted Common Stock"). On January 2, 2017, the reporting person was granted 16,667 restricted stock units, all of which vested on January 2, 2018. Such restricted stock units were previously reported in Table II on a Form 4 filed with the Securities and Exchange Commission on January 5, 2017. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 22:16 UTC |
Billings PaulDirector
|
Exercise / conversionRestricted Stock Units · Derivative | 16,667 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-000484 · doc4.xml · derivative · entry 2 Billings Paul · CIK 0001591558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock. F3 · derivative.exercise_date: On January 2, 2017, the reporting person was granted 16,667 restricted stock units, all of which vested on January 2, 2018. The common stock into which such vested restricted stock units converted on January 2, 2018 is reported in Table I on this Form 4. F3 · derivative.expiration_date: On January 2, 2017, the reporting person was granted 16,667 restricted stock units, all of which vested on January 2, 2018. The common stock into which such vested restricted stock units converted on January 2, 2018 is reported in Table I on this Form 4. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 22:16 UTC |
Billings PaulDirector
|
Exercise / conversionCommon Stock | 16,667 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-000484 · doc4.xml · nonDerivative · entry 1 Billings Paul · CIK 0001591558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,667 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion upon vesting of restricted stock units into common stock (the "Converted Common Stock"). On January 2, 2017, the reporting person was granted 16,667 restricted stock units, all of which vested on January 2, 2018. Such restricted stock units were previously reported in Table II on a Form 4 filed with the Securities and Exchange Commission on January 5, 2017. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 22:15 UTC |
Markin Rodney SDirector
|
Exercise / conversionRestricted Stock Units · Derivative | 16,667 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-000480 · doc4.xml · derivative · entry 2 Markin Rodney S · CIK 0001393415 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock. F3 · derivative.exercise_date: On January 2, 2017, the reporting person was granted 16,667 restricted stock units, all of which vested on January 2, 2018. The common stock into which such vested restricted stock units converted on January 2, 2018 is reported in Table I on this Form 4. F3 · derivative.expiration_date: On January 2, 2017, the reporting person was granted 16,667 restricted stock units, all of which vested on January 2, 2018. The common stock into which such vested restricted stock units converted on January 2, 2018 is reported in Table I on this Form 4. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 22:15 UTC |
Markin Rodney SDirector
|
Exercise / conversionCommon Stock | 16,667 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-000480 · doc4.xml · nonDerivative · entry 1 Markin Rodney S · CIK 0001393415 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,610 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion upon vesting of restricted stock units into common stock (the "Converted Common Stock"). On January 2, 2017, the reporting person was granted 16,667 restricted stock units, all of which vested on January 2, 2018. Such restricted stock units were previously reported in Table II on a Form 4 filed with the Securities and Exchange Commission on January 5, 2017. Read SEC document |
| October 04, 2017 Filed Oct 5, 2017 20:19 UTC |
JACOB GARY SDirector
|
GrantStock Options · Derivative | 38,106 | $0.00 Strike: $0.72 | $0.00 |
DisclosureSEC source: 0001104659-17-061153 · a4.xml · derivative · entry 1 JACOB GARY S · CIK 0001266802 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,779 Underlying: Common Stock · 38,106 shares Expires 2027-10-04 Read SEC document |
| October 04, 2017 Filed Oct 5, 2017 16:18 UTC |
ADAMS THOMAS PHDDirector
|
GrantStock Options · Derivative | 38,106 | $0.00 Strike: $0.72 | $0.00 |
DisclosureSEC source: 0001104659-17-061150 · a4.xml · derivative · entry 1 ADAMS THOMAS PHD · CIK 0001234366 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 412,955 Underlying: Common Stock · 38,106 shares Expires 2027-10-04 Read SEC document |
| October 04, 2017 Filed Oct 5, 2017 20:21 UTC |
Tennant StanleyDirector
|
GrantStock Options · Derivative | 38,106 | $0.00 Strike: $0.72 | $0.00 |
DisclosureSEC source: 0001104659-17-061156 · a4.xml · derivative · entry 1 Tennant Stanley · CIK 0001526214 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,264 Underlying: Common Stock · 38,106 shares Expires 2027-10-04 Read SEC document |
| October 04, 2017 Filed Oct 5, 2017 20:20 UTC |
Markin Rodney SDirector
|
GrantStock Options · Derivative | 38,106 | $0.00 Strike: $0.72 | $0.00 |
DisclosureSEC source: 0001104659-17-061154 · a4.xml · derivative · entry 1 Markin Rodney S · CIK 0001393415 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,336 Underlying: Common Stock · 38,106 shares Expires 2027-10-04 Read SEC document |
| October 04, 2017 Filed Oct 5, 2017 20:18 UTC |
BRANCACCIO JOHN PDirector
|
GrantStock Options · Derivative | 38,106 | $0.00 Strike: $0.72 | $0.00 |
DisclosureSEC source: 0001104659-17-061152 · a4.xml · derivative · entry 1 BRANCACCIO JOHN P · CIK 0001276551 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,808 Underlying: Common Stock · 38,106 shares Expires 2027-10-04 Read SEC document |
| October 04, 2017 Filed Oct 5, 2017 20:18 UTC |
Billings PaulDirector
|
GrantStock Options · Derivative | 38,106 | $0.00 Strike: $0.72 | $0.00 |
DisclosureSEC source: 0001104659-17-061151 · a4.xml · derivative · entry 1 Billings Paul · CIK 0001591558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,336 Underlying: Common Stock · 38,106 shares Expires 2027-10-04 Read SEC document |
| September 05, 2017 Filed Sep 6, 2017 21:02 UTC |
Tennant StanleyDirector
|
SaleCommon Stock | 8,334 | $0.69 | $5,750.46 |
DisclosureSEC source: 0001104659-17-055831 · a4.xml · nonDerivative · entry 1 Tennant Stanley · CIK 0001526214 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,394 Read SEC document |
| September 02, 2017 Filed Sep 6, 2017 20:41 UTC |
Erlander MarkChief Scientific Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 30,001 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-055891 · a4.xml · derivative · entry 3 Erlander Mark · CIK 0001651537 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,000 Underlying: Common Stock · 30,001 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock. F4 · derivative.exercise_date: On January 2, 2017, the reporting person was granted 30,001 restricted stock units, all of which vested on September 2, 2017. The common stock into which such vested restricted stock units converted on September 2, 2017 is reported in Table I on this Form 4. F4 · derivative.expiration_date: On January 2, 2017, the reporting person was granted 30,001 restricted stock units, all of which vested on September 2, 2017. The common stock into which such vested restricted stock units converted on September 2, 2017 is reported in Table I on this Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.